For patients who tolerated and remained on therapy, the average treatment effect on serum phosphorus was about -0.7mg/dL.
The new Nordic renal diet is a plant-focused meal pattern with reduced phosphorus and protein content and more fiber compared with an average Danish diet.
Nearly two-thirds of patients receiving dialysis use phosphate binders intermittently, a study found.
Use of home dialysis and modalities other than conventional in-center hemodialysis is expected to grow.
Study findings suggest serum phosphate is a negative modulator of calcium receptor activation.
Patiromer may be another therapeutic option for patients with both hyperkalemia and hyperphosphatemia.
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Full results from the OPTIMIZE study, due to be completed in August 2021, are forthcoming.